Non-selective Ionotropic Glutamate
Agonists |
Cat. No. | Product Name / Activity |
|---|---|
| 0217 | D-Glutamic acid |
| Endogenous, non-selective agonist. Less active enantiomer | |
| 0218 | L-Glutamic acid |
| Endogenous, non-selective glutamate receptor agonist | |
Antagonists |
Cat. No. | Product Name / Activity |
| 3699 | DL-AP4 Sodium salt |
| Broad spectrum glutamatergic antagonist; sodium salt of DL-AP4 (Cat. No. 0101) | |
| 0102 | D-AP4 |
| Broad spectrum glutamatergic antagonist | |
| 0101 | DL-AP4 |
| Broad spectrum glutamatergic antagonist | |
| 0328 | (R)-3-Carboxy-4-hydroxyphenylglycine |
| Ionotropic glutamate receptor antagonist | |
| 1395 | (R)-3,4-DCPG |
| AMPA antagonist/weak NMDA antagonist | |
| 1394 | (RS)-3,4-DCPG |
| Potent systemically active anticonvulsant. Racemate of (R)-3,4,-DCPG (Cat. No. 1395) | |
| 0112 | γDGG |
| Broad spectrum glutamatergic antagonist | |
| 0223 | Kynurenic acid |
| Broad spectrum glutamatergic antagonist | |
| 3694 | Kynurenic acid sodium salt |
| Sodium salt of kynurenic acid (Cat. No. 0223) | |
Other |
Cat. No. | Product Name / Activity |
| 0310 | (RS)-4-Carboxy-3-hydroxyphenylglycine |
| Broad spectrum glutamatergic antagonist | |
| 1490 | MNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate | |
Ion Channel Product Listing
Highlights around 500 products for ion channel research.
Request copyDownload PDFPain Research Product Guide
Our Pain guide highlights over 280 products for Pain research.
Request copyDownload PDFEpilepsy Life Science Poster
Written by Alsa Pitkänen and Xavier Ekolle Ndode-Ekane, this poster summarizes current knowledge about how epilepsy develops.
Request copyDownload PDFPain Life Science Poster
Written by Grant D. Nicol and Michael R. Vasko
Our Peripheral Sensitization poster gives a summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization.
Request copyDownload PDFParkinson's Life Science Poster
Written by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF